NCT05786924 2026-04-21Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive MalignanciesServierPhase 1/2 Recruiting554 enrolled
NCT04485013 2026-02-18TTX-080 HLA-G Antagonist in Subjects With Advanced CancersTizona Therapeutics, IncPhase 1 Recruiting240 enrolled